Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms (ATLAS)

3. november 2026 opdateret af: Biogen

Et fase 3 randomiseret, placebokontrolleret forsøg med en longitudinel naturhistorie indkøring og open-label udvidelse til evaluering af BIIB067 påbegyndt hos klinisk præsymptomatiske voksne med en bekræftet superoxiddismutase 1-mutation

In this study, researchers will learn more about the effects of a drug called tofersen, also known as BIIB067 and QALSODY®, in adults with amyotrophic lateral sclerosis (ALS) who have a superoxide dismutase 1 (SOD1) gene mutation.

One of the causes of ALS is a change (or mutation) in the SOD1 gene, which causes abnormal SOD1 protein to be made. This abnormal protein can cause the motor neurons in people with ALS to break down and die. When neurons are damaged, they release a protein called neurofilament light chain, also known as NfL. Previous studies have shown that NfL levels are higher in people with SOD1-ALS, even before any ALS symptoms appear.

In this study, researchers will look at the effect of tofersen treatment in the earlier stages of the disease, even before ALS symptoms appear. Researchers believe that giving tofersen to patients as early as possible may slow the onset of ALS symptoms and the progression of the disease.

This study will have 4 parts. In Part A, participants will have their health monitored and NfL levels tested on a monthly basis, but they will not receive any study drug. Tofersen or placebo will be given to participants in Parts B, while all participants will receive tofersen in Parts C and D.

The main question that researchers want to answer is:

• How long does it take for ALS symptoms to appear?

Researchers will also learn more about:

  • How many participants develop ALS symptoms within 24 months of the start of Part B
  • Changes in participants' ability to perform their daily activities
  • Changes in participants' ability to breathe
  • How many participants die or need long-term breathing support
  • Changes in NfL levels in the blood
  • Changes in SOD1 protein levels in the fluid around the brain and spinal cord
  • How many participants have adverse events or serious adverse events. Adverse events are health problems that may or may not be caused by the study drug.

The study will be done as follows:

  • Participants will first be screened to check if they can join the study. The screening period will be up to 6 weeks. Participants will join the study only after reading and signing an informed consent form, also known as an ICF.
  • In Part A, participants with presymptomatic ALS will not get any study drugs. Researchers will check the levels of NfL in their blood. Participants will be closely checked for any signs or symptoms of ALS.
  • Once a participant's NfL levels rise to a certain amount, they will move onto Part B.
  • In Part B, participants will be randomly assigned to get either tofersen or a placebo. Neither participants nor researchers will know who gets tofersen or the placebo during Part B. A placebo looks like the study drug but contains no medicine.
  • Participants will get the first 3 doses of tofersen once every 14 days. Afterwards, they will continue getting maintenance doses every 28 days.
  • All doses will be given through an intrathecal (IT) injection done through a lumbar puncture procedure. This involves injecting the drug into the fluid surrounding the spinal cord in the lower back.
  • Participants who develop ALS symptoms during Part B will move to Part C to receive tofersen.
  • Participants who develop ALS symptoms during Part A will move to Part D to receive tofersen.
  • In both Parts C and D, participants will know they are receiving tofersen.
  • Throughout the study, doctors will measure any changes to the participants' function and quality of life using different questionnaires. Doctors will also take blood and urine samples. They will also check the participants' overall health and ask how they are feeling.
  • Participants will have a follow-up visit 28 days after their last dose of study drug.
  • Participants will be in this study for up to about 6.5 years.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Intervention / Behandling

Detaljeret beskrivelse

The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability of tofersen and to evaluate the effect of tofersen on pharmacodynamics (PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of clinically manifest ALS.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

158

Fase

  • Fase 3

Udvidet adgang

Godkendt til salg til offentligheden. Se udvidet adgangsregistrering.

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New South Wales
      • Macquarie Park, New South Wales, Australien, 2109
        • Macquarie University Hospital
      • Leuven, Belgien, 3000
        • UZ Leuven
      • São Paulo, Brasilien, 04038-002
        • PSEG Centro de Pesquisa Clinica
    • São Paulo
      • São Paulo, São Paulo, Brasilien, 04037-002
        • Hospital Sao Paulo
    • Alberta
      • Calgary, Alberta, Canada, T2N4Z6
        • University of Calgary
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Sunnybrook Health Sciences Centre
    • Quebec
      • Montreal, Quebec, Canada, H4A 3T2
        • Genge Partners
    • South Yorkshire
      • Sheffield, South Yorkshire, Det Forenede Kongerige, S10 2RX
        • University of Sheffield
    • Arizona
      • Scottsdale, Arizona, Forenede Stater, 85258
        • HonorHealth Neurology
    • California
      • La Jolla, California, Forenede Stater, 92093-0949
        • University of California San Diego Medical Center
      • San Francisco, California, Forenede Stater, 94107
        • California Pacific Medical Center Research Institute
    • Florida
      • Fort Lauderdale, Florida, Forenede Stater, 33308
        • Holy Cross Hospital
      • Miami, Florida, Forenede Stater, 33136
        • University of Miami School of Medicine
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322-4200
        • The Emory Clinic
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Northwestern Medicine
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287
        • Johns Hopkins Hospital
    • Massachusetts
      • Charlestown, Massachusetts, Forenede Stater, 02129
        • Massachusetts General Hospital, MA
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110
        • Washington University School of Medicine
    • New York
      • New York, New York, Forenede Stater, 10032
        • Columbia University Medical center
    • Texas
      • Austin, Texas, Forenede Stater, 78756
        • Austin Neuromuscular Center
    • Paris
      • Paris, Paris, Frankrig, 75651
        • Groupe Hospitalier Pitie-Salpetriere
      • Torino, Italien, 10124
        • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japan, 890-8520
        • Kagoshima University Hospital
    • Tokyo-To
      • Bunkyō City, Tokyo-To, Japan, 113-8655
        • University of Tokyo Hospital
      • Warsaw, Polen, 01-684
        • Centrum Medyczne NeuroProtect
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polen, 01-684
        • NeuroProtect Sp. z o.o.
      • Valencia, Spanien, 46026
        • Hospital Universitari i Politecnic La Fe
      • Umeå, Sverige, 90185
        • Norrlands Universitetssjukhus
    • Västerbotten County
      • Umeå, Västerbotten County, Sverige, 90185
        • University Hospital of Umea
      • Seoul, Sydkorea, 04763
        • Hanyang University Seoul Hospital
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Tyskland, 89081
        • Universitaetsklinikum Ulm
    • Lower Saxony
      • Hanover, Lower Saxony, Tyskland, 30625
        • Medizinische Hochschule Hannover

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Part A Inclusion Criteria:

  • Participants should have a protocol-defined rapidly progressive SOD1 mutation, confirmed by a central reader, or a SOD1 mutation that is approved for inclusion by an external mutation adjudication committee.
  • Participants with plasma NfL level less than the protocol-defined threshold.
  • Participants who are clinically presymptomatic for ALS (i.e., must not have clinically manifest ALS).

Key Part A Exclusion Criteria:

  • History or positive test result at screening for human immunodeficiency virus (HIV). The requirement for testing at Screening may be omitted if it is not permitted by local regulations.

  • Current hepatitis C infection [defined as positive Hepatitis C Virus (HCV) antibody and detectable HCV ribonucleic acid (RNA)]. Participants with positive HCV antibody and undetectable HCV RNA are eligible to participate in the study (United States Centers for Disease Control and Prevention).

  • Current hepatitis B infection (defined as positive for hepatitis B surface antigen (HBsAg) and/or anti-Hepatitis B Core antibody (HBc)). Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive anti-HBc, and positive anti-hepatitis B surface antibody (HBs) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti- HBs) are eligible to participate in the study.

  • History of systemic hypersensitivity reaction to tofersen, the excipients contained in the formulation, and if appropriate, any diagnostic agents to be administered during the study.

  • History of confounding neuromuscular or neurological disorder that is expected to have a progressive (i.e., worsening) course during the study, and/or is expected to be associated with elevations in NF, in the opinion of the Investigator.

  • Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that if not managed optimally could place a participant at an increased risk for intraoperative or postoperative bleeding.

  • Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, suicidal ideation, suicide attempt, or untreated major depression

    ≤ 90 days of screening, which in the opinion of the Investigator would interfere with the study procedures.

  • Treatment with riluzole, edaravone, and/or sodium phenylbutyrate/taurursodiol (also known as ursodoxicoltaurine). If the participant has been on riluzole, edaravone, and/or sodium phenylbutyrate/taurursodiol, the medication(s) must be discontinued for at least 5 half-lives prior to Screening.

  • Use of off-label treatments for ALS.

  • Treatment with another investigational drug (including investigational drugs for ALS through compassionate use programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering RNA, stem cell therapy, or gene therapy is allowed.

  • Anticipated need, in the opinion of the Investigator, for administration of any antiplatelet or anticoagulant medication (e.g., clopidogrel) that cannot be safely continued or held for a Lumbar Puncture (LP) procedure, if necessary, according to local or institutional guidelines and/or Investigator determination.

  • Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment, biological agent, device, or approved therapy for investigational use. Participation in a noninterventional study focused on ALS natural history may be allowed at the discretion of the Investigator.

NOTE: Other protocol defined Inclusion/Exclusion criteria will apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Part A: Natural History Run-in

Participants enrolled in Part A will undergo blood draws approximately once every 28 days to assess NfL levels.

Eksperimentel: Part B: Randomized, Double-Blind, Placebo-Controlled

Participants from Part A who meet the protocol-defined NfL threshold and remain presymptomatic may be eligible to participate in Part B. During Part B, participants will receive tofersen 100 milligrams (mg) or placebo via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to approximately 5.6 years.

Administered as specified in the treatment arm

Administered as specified in the treatment arm

Andre navne:
  • BIIB067
  • QALSODY
Eksperimentel: Part C: Open-Label Extension

Participants from Part B who develop clinically manifest ALS may be eligible to participate in Part C. During Part C, participants who received placebo in Part B will receive tofersen 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter up to the final maintenance dose visit. Participants who received tofersen during Part B will receive tofersen 100 mg on Days 1, 29, and every 28 days thereafter up to the final maintenance dose visit, with a dose of placebo on Day 15 to maintain the study blind. The combined duration of Part B and Part C is up to approximately 5.6 years.

Administered as specified in the treatment arm

Administered as specified in the treatment arm

Andre navne:
  • BIIB067
  • QALSODY
Eksperimentel: Part D: Open-Label Treatment

Participants from Part A who develop clinically manifest ALS prior to randomization in Part B may be eligible to participate in Part D. During Part D, participants will receive tofersen 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.

Administered as specified in the treatment arm

Andre navne:
  • BIIB067
  • QALSODY

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Part B: Time to Emergence of Clinically Manifest ALS
Tidsramme: Up to 5.6 years
Up to 5.6 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Del B og C: Procentdel af deltagere med fremkomst af klinisk manifest ALS inden for 24 måneder efter del B-baseline
Tidsramme: Op til 24 måneder
Op til 24 måneder
Del B og C: Ændring fra baseline i procent forudsagt langsom vitalkapacitet (SVC)
Tidsramme: Op til 5,6 år
Op til 5,6 år
Del B og C: Procentdel af deltagere med udfald som dødsfald baseret på analyse af tid til død
Tidsramme: Op til 5,6 år
Op til 5,6 år
Del B, C og D: Antal deltagere med uønskede hændelser (AE'er) og alvorlige bivirkninger (SAE'er) i løbet af behandlingsperioden
Tidsramme: Del B og C: Op til 5,6 år og Del D: Op til 2 år
Del B og C: Op til 5,6 år og Del D: Op til 2 år
Del B, C og D: Ændring fra baseline i plasma NfL-koncentrationer
Tidsramme: Del B og C: Op til 5,6 år og Del D: Op til 2 år
Del B og C: Op til 5,6 år og Del D: Op til 2 år
Del B, C og D: Ændring i total cerebrospinalvæske (CSF) SOD1-koncentrationer
Tidsramme: Del B og C: Op til 5,6 år og Del D: Op til 2 år
Del B og C: Op til 5,6 år og Del D: Op til 2 år
Parts B and C: Change in ALS Functional Rating Scale (ALSFRS-R) Total Score
Tidsramme: Up to 5.6 years

The ALSFRS-R measures 4 functional domains: respiratory, bulbar function, gross motor skills, and fine motor skills. There are 12 questions, each scored from 0 to 4, for a total possible score of 48, with higher scores representing better function.

Up to 5.6 years
Parts B and C: Percentage of Participants with Outcome as Death or Permanent Ventilation Based on Time to Death or Permanent Ventilation Analysis
Tidsramme: Up to 5.6 years

Permanent ventilation is defined as ≥22 hours of invasive or non-invasive mechanical ventilation per day for ≥21 consecutive days.

Up to 5.6 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Medical Director, Biogen

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. maj 2021

Primær færdiggørelse (Anslået)

7. august 2027

Studieafslutning (Anslået)

25. maj 2028

Datoer for studieregistrering

Først indsendt

20. april 2021

Først indsendt, der opfyldte QC-kriterier

20. april 2021

Først opslået (Faktiske)

23. april 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 233AS303
  • 2023 (U.S. NIH-bevilling/kontrakt)
  • 2023-505641-12 (Anden identifikator: EU Trial (CTIS) Number)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner